Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

  /  

Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

CAMBRIDGE, Mass., April 5, 2021 – Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance. In this newly created role, Ms. Riethuisen will oversee corporate development, finance and strategic planning and serve as treasurer and company secretary.

“We are thrilled to welcome Véronique to Cedilla. She has an impressive track record shaping and building early and late-stage portfolios for leading biopharmaceutical companies,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Véronique’s substantial leadership experience, coupled with her background in corporate and business development, will be instrumental in growing Cedilla. We look forward to her contributions as we execute on our vision of leveraging our novel small molecule drug discovery approach to address the needs of patients with cancer and other diseases.”

“I am honored to join the Cedilla team. Cedilla has developed a novel approach to addressing undruggable targets for the treatment of cancers and diseases caused by protein dysregulation,” said Ms. Riethuisen. “I look forward to working together with my new colleagues to progress a growing portfolio of promising medicines for the benefit of patients.”

Ms. Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla. Most recently, Ms. Riethuisen served as Senior Vice President, Global Business Development and Strategic Alliance Management at Ipsen where she helped build Ipsen’s rare disease franchise by acquiring and licensing multiple innovative assets for the treatment of fibrodysplasia ossificans progressiva. She also negotiated Ipsen’s global agreement with Debiopharm for Decapeptyl®, an achievement recognized with the 2020 Award for “Long-Established Alliance” from the Association of Strategic Alliance Professionals. Prior to Ipsen, Ms. Riethuisen was Vice President, Head of Global Transactions at Takeda where she led a team that, in just one year, successfully landed over 20 deals transforming the company’s gastrointestinal and regenerative medicine portfolios. Earlier, Ms. Riethuisen held various business development, M&A and alliance management roles of increasing responsibility at Pfizer, Teva, Bristol Myers Squibb and Monsanto.  Ms. Riethuisen currently serves as an Executive Coach for the MassNextGen program mentoring first-time female chief executive officers, and she teaches a Business Development Fundamentals course annually in conjunction with the BIO Annual Conference. Ms. Riethuisen holds a bachelor and master’s degree in Applied Economics from the University of Brussels (ULB), Belgium.

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-120

Associate Director / Director, Computational Chemistry

Associate Director / Director, Computational Chemistry

We are looking for a scientist with broad expertise in computational chemistry, chemical informatics, and small molecule drug discovery.  You will help move our programs from target selection and hit finding through clinical candidate selection.  You will also be responsible for developing and implementing internal and commercial tools to enable Cedilla’s platform and programs.  Intellectual and scientific curiosity, flexibility, personal motivation and drive are key attributes for all members of our team.

Job Responsibilities:

  • Define appropriate modeling software needs to support all medicinal chemistry and cheminformatics efforts, in collaboration with IT/Research Informatics colleagues.
  • Work with project teams to generate structural hypotheses for new analog design, as part of our Design/Make/Test/Analyze cycles.
  • Execute both structure-based and ligand-based work-flows, including development of pharmacophore and QSAR models, ligand docking, virtual screening, protein-protein interaction, MD simulation and energy perturbation calculations.
  • Develop methodologies to inform on protein conformational space accessibility, including free energy methods and energetic analysis.
  • Develop custom tools to enable data analysis, sharing and visualization.
  • Provide scientific leadership within a multi-disciplinary drug discovery team, particularly providing guidance to internal and external chemistry teams for new target designs.

Job Requirements:

  • Ph.D. in computational chemistry, chemical informatics, physical organic chemistry, biophysics or related field.
  • 8 years of relevant pharmaceutical industry experience on multiple successful small molecule programs.
  • Solid understanding of chemometrics, which includes QSAR methodologies, pharmacophore development, 2D and 3D similarity, data mining and visualization, protein modeling, conformational analysis, molecular docking, library analysis and design.
  • Ability to work across various disciplines involved in small molecule drug discovery, including working with colleagues in Computational Biology and Computational Proteomics.
  • Expertise in medicinal chemistry and basic knowledge of synthetic organic chemistry.
  • Ability to work independently within a collaborative environment while demonstrating leadership, creativity and adaptability in your scientific work.
  • Strong analytical and problem-solving skills and scientific creativity are essential.
  • Strong scientific programming skills (Perl, Python, R, Linux) and expertise with pipelining tools (Knime, Pipeline Pilot)

Cedilla is an equal opportunity employer. We recruit, employ, train, compensate, and promote without regard to race, religion, creed, national origin, age, gender, sexual orientation, sexual identity, marital status, military or veteran status, disability, genetic information, or any other category protected by applicable federal, state or local law.

Cedilla does not accept unsolicited agency resumes. Staffing agencies should not send resumes to our HR team or to any Cedilla employees. Cedilla is not responsible for any fees related to unsolicited resumes from staffing agencies.

*To apply, please submit your resume to careers@cedillatx.com

Jack Taunton, Ph.D.

  /  

Jack Taunton, Ph.D.

Jack Taunton has spent much of his career developing biochemical tools to illuminate cellular processes relevant to cancer and autoimmune diseases. His work designing covalent inhibitors that target protein kinases led to a drug candidate that’s now advancing through clinical trials. He also discovered a family of cyclic depsipeptides that represent a promising new class of oncology drugs. Jack earned his Ph.D. in chemistry from Harvard University and is a co-founder of Global Blood Therapeutics, Principia Biopharma and Kezar Life Sciences.

William Kaelin, Jr., M.D.

  /  

William Kaelin, Jr., M.D.

Bill Kaelin’s distinguished research career has focused on the proteins encoded by tumor suppressor genes and how mutations in those genes cause cancer. His work on the VHL protein delivered new insights into how cells respond to changes in oxygen levels – and motivated the successful clinical testing of VEGF inhibitors, which are now approved to treat kidney cancer. A professor at the Dana-Farber Cancer Institute and Harvard Medical School, Bill brings deep expertise in the regulation of oncoproteins to Cedilla. He also brings a unique cell-based assay that quickly screens cells to find upstream regulators that control the stability of proteins. Bill has won many top scientific honors, including the Nobel Prize in medicine or physiology, the ASCO Science of Oncology Award, the Canada Gairdner International Award and the Albert Lasker Award for Basic Medical Research. He sits on the editorial board of numerous journals, including Cancer Cell, and has served on the National Cancer Institute’s Board of Scientific Advisors. Bill received his M.D. from Duke University

Matthew Jacobson, Ph.D.

  /  

Matthew Jacobson, Ph.D.

Matt Jacobson is a veteran researcher and entrepreneur with deep experience in both molecular biophysics and drug discovery. A professor at the University of California, San Francisco School of Pharmacy, Matt focuses on research including predicting protein function and regulation, creating new methods for computer-aided drug design and investigating new approaches to treating neurodegenerative diseases.  Matt, who earned his Ph.D. in physical chemistry from MIT, is also a co-founder of Circle Pharma, Relay Therapeutics and Global Blood Therapeutics. He serves on the scientific advisory board of Schrodinger LLC.

Steve Gygi, Ph.D.

  /  

Steve Gygi, Ph.D.

Steve Gygi brings a deep expertise in mass spectrometry and proteomics, with a particular focus on detecting and quantifying the changes that ensue after a protein is perturbed by an external event, such as pharmacological or pathological intervention. A professor of cell biology at Harvard Medical School, Steve specializes in developing technologies for rapid, sensitive and multifaceted analysis of proteins. His lab co-published a protein interaction network, the BioPlex, that includes more than 9,000 proteins. Steve received his Ph.D. in pharmacology and toxicology from the University of Utah.

Alan D’Andrea, M.D.

  /  

Alan D’Andrea, M.D.

Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Science and the National Academy of Medicine.

Dominik Naczynski, PhD

  /  

Dominik Naczynski, PhD

Dominik Naczynski, Ph.D., joined Boxer Capital, LLC in 2014. As Senior Vice President, Dr. Naczynski is responsible for conducting due diligence of public and private investments in healthcare. In his role, he also serves as a Member of the Board of Directors for Cedilla Therapeutics, Inc. Dr. Naczynski received a Bachelor of Science degree in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering from Rutgers University. He completed his postdoctoral training in radiation oncology at the Stanford University School of Medicine where his research focused on the application of novel nanomaterials for molecular imaging of cancer. He was also a graduate of the Ignite Program in the Stanford Graduate School of Business.  He has authored and been the recipient of research grants from the National Institutes of Health, National Cancer Institute, and Department of Defense.  He has also published in leading scientific journals and is listed as a co-inventor on several medical device patents.

Andres Tellez, Ph.D.

  /  

Andres Tellez, Ph.D.

Executive Director of Business Development and Strategy

Andres Tellez comes to Cedilla from Syros Pharmaceuticals, where he served as senior director of business development and helped secure the company’s partnerships with Incyte and Johnson and Johnson. Before joining Syros, Andres worked for several years at Cerulean Pharma, rising to director and acting head of business development. At Cerulean he served in a broad role, advancing strategic collaborations and supporting the company’s clinical development and fundraising efforts. Andres has a Ph.D. in biomedical informatics from Stanford University and an SB and M.Eng in EECS from MIT.

Rosana Kapeller, M.D., Ph.D.

  /  

Rosana Kapeller, M.D., Ph.D.

Rosana Kapeller is the co-founder, CEO and president of ROME Therapeutics and a fellow at GV (formerly Google Ventures), focused on the intersection of therapeutics and machine learning. In her former role as the founding CSO at Nimbus Therapeutics, Rosana led the company’s drive to apply advanced computational technologies to the design and development of novel therapeutics. In her eight years at Nimbus, she assembled a strong scientific team that validated the company’s platform and advanced multiple promising programs. Before joining Nimbus, Rosana worked as vice president of research at Aileron Therapeutics. She started her career as a scientist at Millennium Pharmaceuticals, where she advanced through positions of increasing responsibility to director. Rosana has served as an adviser to Atlas Venture and has a consultant to Third Rock Ventures. She holds a Ph.D. in molecular and cellular physiology from Tufts University and a M.D. from Universidade do Estado do Rio de Janeiro in Brazil.